When viewed from an economic distance, high-deductible health plans can appear to be benign, but when we get closer, the anticipated savings – and the illusion of financial safety – can...
The relationship between payer, provider and supplier is complex. What will it take to effectively manage the high cost of care in the joint reconstruction market?
The right data can not only effectively highlight the processes and outcomes that need to be improved, but can also suggest what the best tools for improvement should be.
Expecting change to occur without the support of data is a futile exercise. But by using the power of data, hospitals and their clinicians can implement meaningful change.
The FDA recently achieved two significant firsts in one approval. As the market for biosimilars continues to mature, will these occurrences become more routine?